Business Brief

IBA teams with maker of novel PET agent

Ion Beam Applications and NeuroSurvival Technologies will work together to distribute, as well as optimize the radiochemistry of, NST's molecular imaging agent for apoptosis, the genetically controlled process of cell death associated with many diseases, including cancer. The agent, Aposense, will be distributed to sites participating in multicenter clinical trials to document whether the PET radiotracer incorporating fluorine-18 selectively targets and accumulates within cells undergoing apoptosis. IBA Molecular, a business unit of IBA, provides PET radiopharmaceuticals through a global network of radiopharmacies using 37 cyclotron-equipped manufacturing sites.